Table 3.
HBV Vaccination in HIV-infected patients with isolated anti-HBc.
| Study (year) | Design | Schedule | Anamnestic Response 1 | Total Response Rate | Predictor Factors |
|---|---|---|---|---|---|
| Morsica et al. (2017) [92] | Prospective n = 25 |
20 µg at W0 3 doses if anti-HBs < 100 IU/mL after first dose |
24% | 52.6% | Presence of OBI HCV co-infection |
| Piroth et al. (2016) [93] | Prospective n = 54 |
20 µg at W0 then 40 µg at W5–9–24 (if non-AR) |
46% | W28: 89% M18: 81% |
NA |
| Kaech et al. (2012) [94] | Prospective n = 37 |
20 µg M0 +/− 20 µg M0-1-6 | 22% | 60% | Injected drug use |
|
Chakvetadze et al.
(2010) [95] |
Prospective n = 40 |
20 µg +/− 2-5 doses 20 µg | 32.5% | 40.7% W10 64% W21 |
None |
| Jongjirawisan et al. (2006) [96] | Prospective n = 140 |
20 µg once | 7% | NA | Intravenous drug use, HCV co-infection |
| Gandhi et al. (2005) [97] | Prospective n = 69 |
20 µg W0-4-24 | 16% | 62% | Male, HCV co-infection |
1 AR: Anamnestic response: anti-HBs > 10 IU/mL after one dose of vaccine µg: micrograms; OBI: occult hepatitis B infection; HCV: hepatitis C virus; W: week; NA; not assessed; M: month.